Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps highlight key points presented in Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of GU Cancer. The first Recap focuses on data from the phase III PROSELICA trial comparing cabazitaxel 20 mg/m2 with 25 mg/m2 for metastatic castration-resistant prostate cancer. The second Recap focuses on data from the IMvigor 210 trial of atezolizumab for metastatic urothelial cancer. The third Recap focuses on overall survival data from trials of cabozantinib plus everolimus and of nivolumab for metastatic renal cell carcinoma after antiangiogenic therapy.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb, Ferring, Merck, Novartis, and Sanofi.

Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary Cancers

Release Date: July 28, 2016
Expiration Date: July 28 2017
Media: Internet - based

Activity Overview

This activity is designed to update physicians on the data that has been recently presented at major cancer conferences so they can assess and prepare to apply these findings to their clinical practice to improve patient care.

CME Activity Table of Contents

  • Adjuvant Docetaxel Versus Surveillance After Radical Prostatectomy for High-Risk Prostate Cancer:
    Results of the Phase III SPCG12 Trial
  • Cabazitaxel Versus Docetaxel for Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer:
    Results of the Phase III FIRSTANA Trial
  • Cabazitaxel 20 mg/m2 Versus 25 mg/m2 for Metastatic Castration-Resistant Prostate Cancer After Docetaxel:
    Results of PROSELICA, a Phase III Noninferiority Study
  • Frequency and Characterization of Inherited Mutations in Men With Metastatic Castration-Resistant Prostate Cancer
  • A Phase I Study of the BGJ398 in Previously Treated Advanced/Metastatic Urothelial Cancer:
    Data From an Extended Cohort of Patients With Activating FGFR3 Mutations
  • First-Line Atezolizumab for Cisplatin-Ineligible, Locally Advanced/Metastatic Urothelial Carcinoma:
    Primary Analysis of IMvigor210 Cohort 1
  • PD-L1 Inhibition With Durvalumab For Urothelial Bladder Cancer:
    Results From a Phase I/II Dose Study
  • Efficacy and Safety of Nivolumab Monotherapy in Metastatic Urothelial Cancer:
    Results From the Phase I/II CheckMate 032 Study
  • Overall Survival Data From Trials of Cabozantinib and Nivolumab for Previously Treated, Advanced Renal Cell Carcinoma:
    METEOR and CheckMate 032
  • Putting the Data Together: Treatment Selection and Sequencing for Advanced Renal Cell Carcinoma in the Second Line and Beyond

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with GU malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Explain recent results of clinical trials conducted in patients with GU cancers
  • Discuss emerging evidence in the context of evolving treatment paradigms in clinical settings where patients with GU cancers receive care
  • Evaluate the benefit of clinical trial participation for improving outcomes among patients with GU cancers and limited treatment options

Faculty, Staff, and Planners' Disclosures


Oliver Sartor, MD
Laborde Professor for Cancer Research
Medical Director Tulane Cancer Center
Tulane Medical School
New Orleans, LA
Disclosure: Grant/Research Support: Sanofi, AstraZeneca; Consultant: Sanofi, AstraZeneca.

Sumanta Kumar Pal, MD
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, CA
Disclosure: Consultant: Pfizer, GSK, Novartis, Genentech, Exelixis, BMS; Speaker’s Bureau: Genentech.


The following individuals have no relevant financial relationships with commercial interests:

The staff of PER®, LLC.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By